biopharmaceutical

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 19:30 ET  | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…

4 months ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025 01:00 ET  | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…

4 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

June 18, 2025 16:30 ET  | Source: Cellectar Biosciences, Inc. FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar…

4 months ago

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

June 18, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a…

4 months ago

Winner of the Biotherapies and Bioproduction call for projects under the France 2030 plan, EVerZom receives 3 million in government funding to industrialize its exosome bioproduction technology

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government…

4 months ago

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#Biotech--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the…

4 months ago

AVEROA receives European marketing authorization for XOANACYL, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL…

4 months ago

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…

4 months ago

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration…

4 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2025 16:01 ET  | Source: Nurix Therapeutics, Inc. SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics,…

4 months ago